Jennifer A. Yoon advises clients across the life sciences industry on complex corporate and securities law matters.

Ms. Yoon combines extensive transactional experience and a client-first approach to guide biotechnology and other life sciences companies at every stage of maturity through:

  • Public offerings, including initial public offerings (IPO), follow-on offerings, at-the-market offerings, and private investments in public entities
  • Securities law compliance and public company representation
  • Corporate governance and strategy for early-stage companies
  • Preferred equity financings for early-stage companies

She keenly understands the capital markets implications for life sciences companies and distills complex scientific and legal jargon into actionable client advice. Ms. Yoon develops trusted, long-term relationships to both help clients navigate high-stakes transactions and strategize solutions to day-to-day corporate issues that arise.

A recognized leader at the firm, Ms. Yoon serves on the Ethics Committee and previously served on the Associates Committee.

Before her legal career, Ms. Yoon was a children’s book editor.

Public Offerings and Transactions

Ms. Yoon's experience includes advising on:

  • Frequency Therapeutics’ US$84 million IPO of its common stock
  • Kiniksa Pharmaceuticals’ US$152 million IPO of its common stock
  • Momenta Pharmaceuticals’ US$230 million follow-on offering of its common stock
  • Verona Pharma’s US$79 million offering of its American depositary shares and other follow-on offerings
  • Merus’ US$61 million IPO of its common shares, as well as its:
    • Offering of 5.462 million shares of common stock
    • Financing of up to US$75 million shares of common stock
    • Offering of 5.575 million shares of common stock
    • US$110 million offering
  • Seres Therapeutics’ US$154 million IPO of its common stock
  • SQZ Biotechnologies’ IPO of its common stock
  • Rapid Micro Biosystems’ IPO of its common stock
  • Rhythm Pharmaceuticals’ 2022 financing
  • Atea Pharmaceuticals’ IPO
  • Omega Therapeutics’ IPO
  • Ayala Pharmaceuticals’ IPO
  • Desktop Metal’s convertible notes offering

Public Company Representation

Ms. Yoon’s experience representing US and international public companies in their securities law compliance and other public company matters includes advising:

  • Frequency Therapeutics
  • Kiniksa Pharmaceuticals

Early-Stage Companies

Ms. Yoon’s experience representing early-stage companies in their preferred equity financings and on corporate governance strategy includes advising:

  • Omaha National (check)
  • Oncologie in its Series B convertible preferred share financing

Bar Qualification

  • Massachusetts


  • JD, Northwestern University School of Law, 2013
  • BA, Oberlin College, 2002
    Phi Beta Kappa